Global Alpha-1 Antitrypsin Deficiency Treatment Market: Snapshot
The demand in the global alpha-1 antitrypsin deficiency treatment market is projected to increment at an admirable CAGR of 10.3% during the forecast period of 2017 to 2025, gaining traction from a number of factors such as improvements in the diagnostics of alpha-1 antitrypsin deficiency, improving economic scenario in various emerging economies, ample of opportunities in the development of new products, and high unmet demand across the globe. On the other hand, stringent regulations, high cost of drugs, and limited plasma fractionation capacity are some of the hindrances faced by the market, and until these are overcome, the prosper prosperity will not be achieved.
The global alpha-1 antitrypsin deficiency treatment market is estimated to reach a valuation of US$2,908.1 mn by the end of 2025, notably up from its evaluated worth of US$1,224.5 mn in 2016. The stockholders of the global alpha-1 antitrypsin deficiency treatment market are expected to gain new opportunities in the near future via strategic alliances and growing awareness regarding this deficiency disease.
Augmentation Therapy Profitable Treatment Segment
On the basis of treatment type, the global alpha-1 antitrypsin deficiency treatment market is segmented into augmentation therapy, bronchodilator, corticosteroids, and oxygen therapy. The segment of augmentation therapy, which is further sub-segmented into aralast, prolastin, glassia, and zemaira or respreeza, currently serves the maximum demand in the global alpha-1 antitrypsin deficiency treatment market, and is expected to sustain its position by the end of 2025, followed by bronchodilator treatment segment. Based on end-user, the AATD market gains maximum demand from hospitals, although specialty clinics are projected for most prominent growth rate. This report also segments the alpha-1 antitrypsin deficiency treatment market on the basis of route of administration, into inhalations, parenteral, and oral, and rates parenteral segment as the most profitable route of administration, which is a reflection of benefits such as ease of drug administration and high chances of avoiding first-pass metabolism.
North America and Europe Most Lucrative Regions
Out of the five regions that this report breaks the market for alpha-1 antitrypsin deficiency treatment into, viz. North America, Asia Pacific, Europe, The Middle East and Africa, and Latin America, North America served the maximum demand in 2016, although the share of the demand is likely to slightly decrease towards the end of the forecast period. High prevalence of alpha-1 antitrypsin deficiency among the population of developed countries of the U.S. and Canada, escalting diagnosis rates, high plasma yield, and high per capita health care expenditure are some of the key factors resulting the strong demand from North America. On the other hand, Europe, which is second most lucrative region for the vendors operating in the global alpha-1 antitrypsin deficiency market, is projected for the best CAGR among all the regions, showcasing the increasing awareness regarding alpha-1 antitrypsin deficiency and high prevalence.
Some of the key companies currently competing in the global alpha-1 antitrypsin treatment market are Pfizer Inc., Baxter, AstraZeneca, Grifols S.A., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Kamada Ltd., GlaxoSmithKline Plc., CSL Behring LLC, Shire plc, LFB Biomedicaments S.A., Abeona Therapeutics, Biogen, Applied Genetic Technologies Corp, Baxalta, Arrowhead Research Corporation, ProBioGen, Chiesi Pharmaceuticals, Curaxys, and ProMetic Life Sciences. The landscape of the competition in the global AATD market is largely fragmented, marked by frequent mergers and acquisitions by the leading vendors to maintain their position.
Global Alpha-1 Antitrypsin Deficiency Treatment Market: Overview
Alpha-1 Antitrypsin also referred as AAT, is a type of protein belongs to the class protease inhibitor. This protein is produced in the liver and is primarily functions to protect the lungs and liver from the harmful effects of other protein in the body. The AAT deficiency is genetic disorder that causes low and defective production of AAT proteins in liver which results in the accumulation of AAT in the liver and low amount of it in blood stream. The presence of AAT deficiency can be diagnosed using blood test, genetic tests and biopsy tests. Patients with severe AAT deficiency get affected by liver cirrhosis, chronic obstructive pulmonary diseases (COPD), and emphysema diseases. The diagnosis rate for alpha-1 antitrypsin deficiency across the globe is one of the crucial indicators of the alpha-1 antitrypsin deficiency treatment market. The AAT deficiency disease can be treated using different therapeutic methods such as augmentation therapy, bronchodilators, corticosteroids, oxygen therapy and other treatment methods.
Global Alpha-1 Antitrypsin Deficiency Treatment Market: Trends and Opportunities
The worldwide increase in the incidences and prevalence of respiratory diseases is projected to be key driving factor for the global AAT deficiency market during forecast period. According to the Forum of International Respiratory Societies (FIRS), COPD affects more than 200 million people and is likely to be the fourth leading cause of death in the world by 2030, while asthma affects about 235 million people globally. AAT deficiency is most commonly observed in the North America and European countries which is likely to drive the market. The increasing awareness about AAT deficiency disorder in developed countries, technological development in in the production and purification of Alpha-1 Antitrypsin protein, and government initiatives for increasing blood and plasma derived products would boost the growth of global AAT deficiency treatment market. The AAT deficiency is common, but under diagnosed condition in most of countries. The slow diagnosis rates of AAT deficiency and high cost of treatment is likely to hamper growth of global AAT deficiency treatment market over forecast period. Alpha-1 antitrypsin deficiency (A1AD) mostly occurs in the Caucasian population of European descent, affecting approximately 100,000 Americans. However, most cases of A1AD are undetected, making alpha-1 antitrypsin deficiency a highly under-diagnosed disorder. Also the treatment of AAT deficiency may lead to development of several chronic side effects such as back/joint pain, chest pain, musculoskeletal pain, rhinorrhea, sinusitis, fever, nausea, or shortness of breath, peripheral edema, and urticarial. These side effects can sometimes force a patient to discontinue the therapy as alpha-1 antitrypsin is a natural enzyme inhibitor product.
Global Alpha-1 Antitrypsin Deficiency Treatment Market: Geographical Segmentation
Geographically, the global AAT deficiency treatment market has been segmented into five regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America dominated the global AAT deficiency treatment market in 2016 and is likely to lose its market share to Europe by the end of 2025. Europe is projected to expand at highest CAGR during forecast period and is likely to gain its market share by the end of 2025. All the regions have been further segmented by countries, product type, by material and End-user segments. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global AAT deficiency treatment market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major companies competing in the non-vascular stents market, and profiled in the report include Grifols S.A., AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., CSL Behring LLC, Shire plc, Pfizer Inc., LFB Biomedicaments S.A., Kamada Ltd.
The Global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented as follows:
Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Treatment Type
- Augmentation Therapy
- Oxygen Therapy
Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Route of Administration
Global Alpha-1 Antitrypsin Deficiency Treatment Market, by End-User
- Specialty Clinics
Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Region
- North America
- Asia Pacific
- Latin America
- Middle East & Africa